

LAW FIRM 2.0[®]
FISHERBROYLES
A LIMITED LIABILITY PARTNERSHIP

James W. Hill, MD

James Hill's practice involves patent litigation, prosecution, and post-grant proceedings including inter partes review, as well as strategic counseling, intellectual property due diligence, and licensing. He handles intellectual property matters for clients in a range of industry sectors including medical devices, biotechnology, pharmaceuticals, software, and signal and imaging processing.

Dr. Hill's work has included serving as trial counsel for plaintiffs and defendants in patent infringement suits involving breast and ovarian cancer gene tests, radiology informatics, hospital information systems, orthopedic surgical devices, MRI diffusion tensor imaging, generic drugs in Hatch-Waxman patent litigation, and biologics in suits brought under the Biologics Price Competition and Innovation Act.

Dr. Hill has managed patent portfolios for Fortune 100 and mid-size companies, startups, and universities. He has also led IP due diligence in a variety of matters resulting in millions of dollars in financings and investments, acquisitions, and licensing agreements.

Recognition

- Recommended in the 2016 edition of The Legal 500 United States for healthcare: life sciences
- Named a leading patent professional in California by IAM Patent 1000 - The World's Leading Patent Practitioners, 2014, 2016, and 2017
- Recognized as a leading California lawyer in life sciences by Chambers USA: America's Leading Lawyers for Business in the 2009-2014 editions
- Named a 2013 and 2014 IP Star by Managing IP, a guidebook that identifies leading IP lawyers in the United States
- Selected as a 2004-2009 Southern California Rising Star by Super Lawyers in intellectual property law in Los Angeles magazine.
- Named among the Daily Journal's Top 25 Portfolio Managers

Representative Litigation

Celgene v. Dr. Reddy's Laboratories

Represented Dr. Reddy's Laboratories (DRL) against Celgene in Hatch-Waxman patent infringement litigation involving DRL's abbreviated new drug application to the FDA for a generic version of Revlimid (lenalidomide).

Amgen v. AbbVie

Represented AbbVie against Amgen in patent infringement litigation and *inter partes* reviews related to Amgen's FDA application for a biosimilar (generic) version of Humira (adalimumab) under the Biologics Price Competition and Innovation Act (BPCIA).

james.hill@fisherbroyles.com

Direct: (424) 285-0188

Practice Areas

Commercial Transactions
Intellectual Property
Internet & eCommerce
Litigation — Appellate
Litigation — Civil Pretrial and Trial Services
Technology

Bar Admissions

California
U.S. Patent and Trademark Office
U.S. District Court for the Central District of California
U.S. District Court for the Eastern District of California
U.S. District Court for the Northern District of California
U.S. District Court for the Southern District of California
U.S. District Court for the Eastern District of Texas
Federal Circuit Court of Appeals

Education

Boston University, *JD, cum laude*
University of Southern California, *MD, with honors*
Residency in diagnostic radiology, Massachusetts General Hospital and Harvard Medical School
Residency in internal medicine, Huntington Memorial Hospital, Pasadena, CA
Harvard Business School, Credential of Readiness (CORe), Business Analytics, Financial Accounting, Economics for Managers, 2016
University of Southern California Viterbi School of Engineering, coursework toward MSEE with emphasis in signal processing, 2004-2008
California State University, Los Angeles, *B.S. program, Biology*

Large Law Firm Experience

Knobbe Martens (Partner)
McDermott Will & Emery (Partner)
WilmerHale (Partner)
Perkins Coie (Partner)

LAW FIRM 2.0[®]

FISHERBROYLES

A LIMITED LIABILITY PARTNERSHIP

Baxter v. Mylan

Represented patent owners Baxter Healthcare S.A. and Baxter International Inc. as lead counsel in *inter partes* reviews of two patents on the cardiac drug esmolol (Brevibloc) filed by Mylan Pharmaceuticals Inc. and Mylan Laboratories Limited.

Prescriber v. Computer Program Systems

Acted as lead trial counsel for defendant Computer Program Systems Inc. (CPSI) in a patent infringement suit by Prescriber, LLC.

University of Utah and Myriad Genetics v Ambry Genetics

Served as trial and appellate counsel for Ambry Genetics in a patent infringement suit by plaintiffs University of Utah and Myriad Genetics involving BRCA1 and BRCA2 breast and ovarian cancer genes and associated genetic testing. Successfully argued that the Federal Circuit Court of Appeals should uphold the Utah District Court's denial of a preliminary injunction against Ambry Genetics. Also won, on patent ineligibility grounds, invalidation of all patent claims at issue directed to DNA probes and primers for cancer genetic testing.

Uniloc v. Computer Program Systems Inc.

Served as lead trial counsel for defendant Computer Program Systems Inc. (CPSI) in a patent infringement suit by Uniloc USA, Inc., and Uniloc Luxembourg S.A.

Myriad Genetics v Gene by Gene

Defended Gene By Gene, acting as trial counsel in a patent infringement suit by Myriad Genetics involving BRCA1 and BRCA2 breast cancer genes and associated genetic testing.

DR Systems v RamSoft

Served as lead trial counsel for defendant RamSoft in a patent infringement suit by DR Systems involving radiology informatics technologies.

DR Systems v Computer Program Systems Inc.

Acted as trial counsel for defendant Computer Program Systems Inc. (CPSI) in a patent infringement suit by DR Systems involving radiology informatics technologies.

NeuroGrafix v. Oak Tree Medical Corporation

Defended Oak Tree Medical Corporation, serving as trial counsel in a patent infringement suit by NeuroGrafix involving MRI neurography.